MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control
Background: The aim of this multicenter observational real-world study was to investigate glycemic outcomes in children and adolescents with type 1 diabetes over the first 6-month use of MiniMed™ 780G. The secondary objective was to evaluate demographic and clinical factors that may be significantly...
Gespeichert in:
| Veröffentlicht in: | Diabetes technology & therapeutics 2023-06, Vol.25 (6), p.404-413 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 413 |
|---|---|
| container_issue | 6 |
| container_start_page | 404 |
| container_title | Diabetes technology & therapeutics |
| container_volume | 25 |
| creator | Lombardo, Fortunato Passanisi, Stefano Alibrandi, Angela Bombaci, Bruno Bonfanti, Riccardo Delvecchio, Maurizio Di Candia, Francesca Mozzillo, Enza Piccinno, Elvira Piona, Claudia Anita Rigamonti, Andrea Scialabba, Francesco Maffeis, Claudio Salzano, Giuseppina |
| description | Background:
The aim of this multicenter observational real-world study was to investigate glycemic outcomes in children and adolescents with type 1 diabetes over the first 6-month use of MiniMed™ 780G. The secondary objective was to evaluate demographic and clinical factors that may be significantly associated with the achievement of therapeutic goals.
Methods:
Demographic, anamnestic, and clinical data of study participants were collected at the time of enrollment. Data on ambulatory glucose profile were acquired at 3 and 6 months after activating automatic mode. Aggregated glucose metrics and device settings of the entire study period were analyzed to identify predictors of optimal glycemic control, assessed by the concomitant achievement of time in range (TIR) >70%, coefficient of variation (CV) |
| doi_str_mv | 10.1089/dia.2022.0491 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2775623436</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2775623436</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-3a5582b181f44bd8f93230a1ec78e9e97b5dd91b6b6e2479cdc6c68ba7b32173</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi1E1ZbSI1fkI5ds_ZHYMbcqwFKpqyKxnCN_TKiR117srKC_oH8bR1t67ckj65l3Zh6E3lGyoqRXV87rFSOMrUir6Ct0TrtONn2n-OulZqRRtBNn6E0pvwghkjN6is64kILzlp-jx42PfgMOy56s8Xf_t9mkON_jHwWwj3i498FliFhHh69dClAsxLngP75C24c9YIo_eW1ghvIRD6GmWR3wVuefULGl7VsG5-2ccsFpwnf72e8qsQ4Hm-qQoY7LKbxFJ5MOBS6f3gu0_fJ5O3xtbu_WN8P1bWM5l3PDddf1zNCeTm1rXD8pzjjRFKzsQYGSpnNOUSOMANZKZZ0VVvRGS1Mvl_wCfTjG7nP6fYAyjztfLwpBR0iHMjIpO8GqGVHR5ojanErJMI37XDfPDyMl46J-rOrHRf24qK_8-6fog9mBe6b_u64APwLLt44xeDCQ5xdi_wG3vpAL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2775623436</pqid></control><display><type>article</type><title>MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Lombardo, Fortunato ; Passanisi, Stefano ; Alibrandi, Angela ; Bombaci, Bruno ; Bonfanti, Riccardo ; Delvecchio, Maurizio ; Di Candia, Francesca ; Mozzillo, Enza ; Piccinno, Elvira ; Piona, Claudia Anita ; Rigamonti, Andrea ; Scialabba, Francesco ; Maffeis, Claudio ; Salzano, Giuseppina</creator><creatorcontrib>Lombardo, Fortunato ; Passanisi, Stefano ; Alibrandi, Angela ; Bombaci, Bruno ; Bonfanti, Riccardo ; Delvecchio, Maurizio ; Di Candia, Francesca ; Mozzillo, Enza ; Piccinno, Elvira ; Piona, Claudia Anita ; Rigamonti, Andrea ; Scialabba, Francesco ; Maffeis, Claudio ; Salzano, Giuseppina</creatorcontrib><description>Background:
The aim of this multicenter observational real-world study was to investigate glycemic outcomes in children and adolescents with type 1 diabetes over the first 6-month use of MiniMed™ 780G. The secondary objective was to evaluate demographic and clinical factors that may be significantly associated with the achievement of therapeutic goals.
Methods:
Demographic, anamnestic, and clinical data of study participants were collected at the time of enrollment. Data on ambulatory glucose profile were acquired at 3 and 6 months after activating automatic mode. Aggregated glucose metrics and device settings of the entire study period were analyzed to identify predictors of optimal glycemic control, assessed by the concomitant achievement of time in range (TIR) >70%, coefficient of variation (CV) <36%, glucose management indicator (GMI) <7%, and time below range (TBR) <4%.
Results:
Our study cohort consisted of 111 children and adolescents (54.1% female) aged 7–18 years. All the most relevant clinical targets were achieved according to recommendations from the International Consensus both at 3 and 6 months. When considering aggregated data, primary goals in terms of TIR, CV, GMI, and TBR were achieved, respectively, by 72.1%, 74.8%, 68.5%, and 74.8% of participants. In addition, 44 individuals (39.6%) concomitantly addressed all the above clinical targets. Regression analysis revealed that older age, briefer duration of disease, and shorter active insulin time were significant predictors of optimal glucose control. Comparing two groups of individuals stratified according to the glycated hemoglobin (HbA1c) mean value in the year preceding MiniMed 780G use, achieving glycemic targets was observed in the subgroup with lower HbA1c.
Conclusions:
Our study highlights the effectiveness and safety of MiniMed 780G in the pediatric population. More extensive and personalized training on advanced hybrid closed-loop use should be considered for younger people and those with long disease duration.</description><identifier>ISSN: 1520-9156</identifier><identifier>EISSN: 1557-8593</identifier><identifier>DOI: 10.1089/dia.2022.0491</identifier><identifier>PMID: 36763343</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc., publishers</publisher><subject>Adolescent ; Benchmarking ; Blood Glucose ; Blood Glucose Self-Monitoring ; Child ; Diabetes Mellitus, Type 1 - drug therapy ; Female ; Glucose ; Glycated Hemoglobin ; Humans ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Insulin Infusion Systems ; Male ; Original Article</subject><ispartof>Diabetes technology & therapeutics, 2023-06, Vol.25 (6), p.404-413</ispartof><rights>2023, Mary Ann Liebert, Inc., publishers</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-3a5582b181f44bd8f93230a1ec78e9e97b5dd91b6b6e2479cdc6c68ba7b32173</citedby><cites>FETCH-LOGICAL-c337t-3a5582b181f44bd8f93230a1ec78e9e97b5dd91b6b6e2479cdc6c68ba7b32173</cites><orcidid>0000-0002-1369-0691 ; 0000-0002-4369-7798 ; 0000-0001-5168-8317 ; 0000-0002-3563-4404 ; 0000-0002-1528-0012</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36763343$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lombardo, Fortunato</creatorcontrib><creatorcontrib>Passanisi, Stefano</creatorcontrib><creatorcontrib>Alibrandi, Angela</creatorcontrib><creatorcontrib>Bombaci, Bruno</creatorcontrib><creatorcontrib>Bonfanti, Riccardo</creatorcontrib><creatorcontrib>Delvecchio, Maurizio</creatorcontrib><creatorcontrib>Di Candia, Francesca</creatorcontrib><creatorcontrib>Mozzillo, Enza</creatorcontrib><creatorcontrib>Piccinno, Elvira</creatorcontrib><creatorcontrib>Piona, Claudia Anita</creatorcontrib><creatorcontrib>Rigamonti, Andrea</creatorcontrib><creatorcontrib>Scialabba, Francesco</creatorcontrib><creatorcontrib>Maffeis, Claudio</creatorcontrib><creatorcontrib>Salzano, Giuseppina</creatorcontrib><title>MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control</title><title>Diabetes technology & therapeutics</title><addtitle>Diabetes Technol Ther</addtitle><description>Background:
The aim of this multicenter observational real-world study was to investigate glycemic outcomes in children and adolescents with type 1 diabetes over the first 6-month use of MiniMed™ 780G. The secondary objective was to evaluate demographic and clinical factors that may be significantly associated with the achievement of therapeutic goals.
Methods:
Demographic, anamnestic, and clinical data of study participants were collected at the time of enrollment. Data on ambulatory glucose profile were acquired at 3 and 6 months after activating automatic mode. Aggregated glucose metrics and device settings of the entire study period were analyzed to identify predictors of optimal glycemic control, assessed by the concomitant achievement of time in range (TIR) >70%, coefficient of variation (CV) <36%, glucose management indicator (GMI) <7%, and time below range (TBR) <4%.
Results:
Our study cohort consisted of 111 children and adolescents (54.1% female) aged 7–18 years. All the most relevant clinical targets were achieved according to recommendations from the International Consensus both at 3 and 6 months. When considering aggregated data, primary goals in terms of TIR, CV, GMI, and TBR were achieved, respectively, by 72.1%, 74.8%, 68.5%, and 74.8% of participants. In addition, 44 individuals (39.6%) concomitantly addressed all the above clinical targets. Regression analysis revealed that older age, briefer duration of disease, and shorter active insulin time were significant predictors of optimal glucose control. Comparing two groups of individuals stratified according to the glycated hemoglobin (HbA1c) mean value in the year preceding MiniMed 780G use, achieving glycemic targets was observed in the subgroup with lower HbA1c.
Conclusions:
Our study highlights the effectiveness and safety of MiniMed 780G in the pediatric population. More extensive and personalized training on advanced hybrid closed-loop use should be considered for younger people and those with long disease duration.</description><subject>Adolescent</subject><subject>Benchmarking</subject><subject>Blood Glucose</subject><subject>Blood Glucose Self-Monitoring</subject><subject>Child</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Female</subject><subject>Glucose</subject><subject>Glycated Hemoglobin</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - therapeutic use</subject><subject>Insulin Infusion Systems</subject><subject>Male</subject><subject>Original Article</subject><issn>1520-9156</issn><issn>1557-8593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi1E1ZbSI1fkI5ds_ZHYMbcqwFKpqyKxnCN_TKiR117srKC_oH8bR1t67ckj65l3Zh6E3lGyoqRXV87rFSOMrUir6Ct0TrtONn2n-OulZqRRtBNn6E0pvwghkjN6is64kILzlp-jx42PfgMOy56s8Xf_t9mkON_jHwWwj3i498FliFhHh69dClAsxLngP75C24c9YIo_eW1ghvIRD6GmWR3wVuefULGl7VsG5-2ccsFpwnf72e8qsQ4Hm-qQoY7LKbxFJ5MOBS6f3gu0_fJ5O3xtbu_WN8P1bWM5l3PDddf1zNCeTm1rXD8pzjjRFKzsQYGSpnNOUSOMANZKZZ0VVvRGS1Mvl_wCfTjG7nP6fYAyjztfLwpBR0iHMjIpO8GqGVHR5ojanErJMI37XDfPDyMl46J-rOrHRf24qK_8-6fog9mBe6b_u64APwLLt44xeDCQ5xdi_wG3vpAL</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Lombardo, Fortunato</creator><creator>Passanisi, Stefano</creator><creator>Alibrandi, Angela</creator><creator>Bombaci, Bruno</creator><creator>Bonfanti, Riccardo</creator><creator>Delvecchio, Maurizio</creator><creator>Di Candia, Francesca</creator><creator>Mozzillo, Enza</creator><creator>Piccinno, Elvira</creator><creator>Piona, Claudia Anita</creator><creator>Rigamonti, Andrea</creator><creator>Scialabba, Francesco</creator><creator>Maffeis, Claudio</creator><creator>Salzano, Giuseppina</creator><general>Mary Ann Liebert, Inc., publishers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1369-0691</orcidid><orcidid>https://orcid.org/0000-0002-4369-7798</orcidid><orcidid>https://orcid.org/0000-0001-5168-8317</orcidid><orcidid>https://orcid.org/0000-0002-3563-4404</orcidid><orcidid>https://orcid.org/0000-0002-1528-0012</orcidid></search><sort><creationdate>202306</creationdate><title>MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control</title><author>Lombardo, Fortunato ; Passanisi, Stefano ; Alibrandi, Angela ; Bombaci, Bruno ; Bonfanti, Riccardo ; Delvecchio, Maurizio ; Di Candia, Francesca ; Mozzillo, Enza ; Piccinno, Elvira ; Piona, Claudia Anita ; Rigamonti, Andrea ; Scialabba, Francesco ; Maffeis, Claudio ; Salzano, Giuseppina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-3a5582b181f44bd8f93230a1ec78e9e97b5dd91b6b6e2479cdc6c68ba7b32173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adolescent</topic><topic>Benchmarking</topic><topic>Blood Glucose</topic><topic>Blood Glucose Self-Monitoring</topic><topic>Child</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Female</topic><topic>Glucose</topic><topic>Glycated Hemoglobin</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - therapeutic use</topic><topic>Insulin Infusion Systems</topic><topic>Male</topic><topic>Original Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lombardo, Fortunato</creatorcontrib><creatorcontrib>Passanisi, Stefano</creatorcontrib><creatorcontrib>Alibrandi, Angela</creatorcontrib><creatorcontrib>Bombaci, Bruno</creatorcontrib><creatorcontrib>Bonfanti, Riccardo</creatorcontrib><creatorcontrib>Delvecchio, Maurizio</creatorcontrib><creatorcontrib>Di Candia, Francesca</creatorcontrib><creatorcontrib>Mozzillo, Enza</creatorcontrib><creatorcontrib>Piccinno, Elvira</creatorcontrib><creatorcontrib>Piona, Claudia Anita</creatorcontrib><creatorcontrib>Rigamonti, Andrea</creatorcontrib><creatorcontrib>Scialabba, Francesco</creatorcontrib><creatorcontrib>Maffeis, Claudio</creatorcontrib><creatorcontrib>Salzano, Giuseppina</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes technology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lombardo, Fortunato</au><au>Passanisi, Stefano</au><au>Alibrandi, Angela</au><au>Bombaci, Bruno</au><au>Bonfanti, Riccardo</au><au>Delvecchio, Maurizio</au><au>Di Candia, Francesca</au><au>Mozzillo, Enza</au><au>Piccinno, Elvira</au><au>Piona, Claudia Anita</au><au>Rigamonti, Andrea</au><au>Scialabba, Francesco</au><au>Maffeis, Claudio</au><au>Salzano, Giuseppina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control</atitle><jtitle>Diabetes technology & therapeutics</jtitle><addtitle>Diabetes Technol Ther</addtitle><date>2023-06</date><risdate>2023</risdate><volume>25</volume><issue>6</issue><spage>404</spage><epage>413</epage><pages>404-413</pages><issn>1520-9156</issn><eissn>1557-8593</eissn><abstract>Background:
The aim of this multicenter observational real-world study was to investigate glycemic outcomes in children and adolescents with type 1 diabetes over the first 6-month use of MiniMed™ 780G. The secondary objective was to evaluate demographic and clinical factors that may be significantly associated with the achievement of therapeutic goals.
Methods:
Demographic, anamnestic, and clinical data of study participants were collected at the time of enrollment. Data on ambulatory glucose profile were acquired at 3 and 6 months after activating automatic mode. Aggregated glucose metrics and device settings of the entire study period were analyzed to identify predictors of optimal glycemic control, assessed by the concomitant achievement of time in range (TIR) >70%, coefficient of variation (CV) <36%, glucose management indicator (GMI) <7%, and time below range (TBR) <4%.
Results:
Our study cohort consisted of 111 children and adolescents (54.1% female) aged 7–18 years. All the most relevant clinical targets were achieved according to recommendations from the International Consensus both at 3 and 6 months. When considering aggregated data, primary goals in terms of TIR, CV, GMI, and TBR were achieved, respectively, by 72.1%, 74.8%, 68.5%, and 74.8% of participants. In addition, 44 individuals (39.6%) concomitantly addressed all the above clinical targets. Regression analysis revealed that older age, briefer duration of disease, and shorter active insulin time were significant predictors of optimal glucose control. Comparing two groups of individuals stratified according to the glycated hemoglobin (HbA1c) mean value in the year preceding MiniMed 780G use, achieving glycemic targets was observed in the subgroup with lower HbA1c.
Conclusions:
Our study highlights the effectiveness and safety of MiniMed 780G in the pediatric population. More extensive and personalized training on advanced hybrid closed-loop use should be considered for younger people and those with long disease duration.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc., publishers</pub><pmid>36763343</pmid><doi>10.1089/dia.2022.0491</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1369-0691</orcidid><orcidid>https://orcid.org/0000-0002-4369-7798</orcidid><orcidid>https://orcid.org/0000-0001-5168-8317</orcidid><orcidid>https://orcid.org/0000-0002-3563-4404</orcidid><orcidid>https://orcid.org/0000-0002-1528-0012</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-9156 |
| ispartof | Diabetes technology & therapeutics, 2023-06, Vol.25 (6), p.404-413 |
| issn | 1520-9156 1557-8593 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2775623436 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Benchmarking Blood Glucose Blood Glucose Self-Monitoring Child Diabetes Mellitus, Type 1 - drug therapy Female Glucose Glycated Hemoglobin Humans Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Insulin Infusion Systems Male Original Article |
| title | MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T06%3A40%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MiniMed%20780G%20Six-Month%20Use%20in%20Children%20and%20Adolescents%20with%20Type%201%20Diabetes:%20Clinical%20Targets%20and%20Predictors%20of%20Optimal%20Glucose%20Control&rft.jtitle=Diabetes%20technology%20&%20therapeutics&rft.au=Lombardo,%20Fortunato&rft.date=2023-06&rft.volume=25&rft.issue=6&rft.spage=404&rft.epage=413&rft.pages=404-413&rft.issn=1520-9156&rft.eissn=1557-8593&rft_id=info:doi/10.1089/dia.2022.0491&rft_dat=%3Cproquest_cross%3E2775623436%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2775623436&rft_id=info:pmid/36763343&rfr_iscdi=true |